Navigation Links
BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:4/5/2011

RALEIGH, N.C., April 5, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today completion of enrollment in its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

(Logo: https://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"The completion of enrollment in our Phase 3 efficacy study marks another very important milestone in our clinical development program for BEMA Buprenorphine in the management of chronic pain," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.  "We are very pleased to have achieved our aggressive recruitment and enrollment goals.  This milestone keeps us on target for reporting top-line study results in the third quarter of this year and is consistent with a timeline that would allow for a New Drug Application (NDA) to be filed in the second quarter of 2012."

BDSI believes that there remains a significant unmet medical need for potent new analgesics for the treatment of chronic pain.  The company believes that buprenorphine is an attractive option for development because of its potent analgesic properties, its differentiating characteristics from other opioids and its DEA Schedule III designation, which means there is less addiction potential than Schedule II products.  In addition, BEMA Buprenorphine has the potential to be the first oral transmucosal form of buprenorphine to treat chronic pain in the U.S.  According to Wolters Kluwer, opioid analgesic sales in the U.S. are in excess of $10 billion and growing, and BDSI believes that BEMA Buprenorphine has the potential to exceed $500 million in peak annual sales.

Additional Information on Phase 3 Study Design (BUP-301)

This Phase 3 trial of BEMA Buprenorphine (referred to as BUP-301) is
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
6. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
7. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
10. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
11. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 UBM Medica US today announced ... online community and information resource for neurologists and other ... their patients with neurological disorders . ... population, necessitates greater access to dedicated information for healthcare ... neurological conditions include: , 1 in 6 ...
(Date:7/23/2014)... OSCEOLA, Wis. and MOUNTAIN VIEW, ... Inc. ("Surpass"), a recognized leader in translational preclinical research, ... at www.surpassinc.com ), signaling the transformation of Surpass, ... integrated innovation partner for our customers. This press release ... that two integral hires were added to the Silicon ...
(Date:7/23/2014)... , July 23, 2014 NOT ... DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE ... LAWS OR REGULATIONS OF SUCH JURISDICTION. AbbVie (NYSE: ... results on Friday, July 25, 2014, before the market opens. ... earnings conference call at 8 a.m. Central time (9 a.m. ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3AbbVie to Host Second-Quarter Earnings Conference Call 2AbbVie to Host Second-Quarter Earnings Conference Call 3AbbVie to Host Second-Quarter Earnings Conference Call 4AbbVie to Host Second-Quarter Earnings Conference Call 5AbbVie to Host Second-Quarter Earnings Conference Call 6
... , , New collaborative research program to study effects ... Dec. 30 A new research program called the Medication ... to study the effects of prescription medications used during pregnancy. ... Drug Administration and researchers at the HMO Research Network Center ...
... , BOSTON, Dec. 30 Solos Endoscopy, Inc. (Pink ... to a prosperous 2010, following a solid year in 2009, due ... the closing months of 2009, Solos Endoscopy, Inc. has taken the ... of surgical endoscopy instruments. This will allow the MammoView(TM) line to ...
Cached Medicine Technology:FDA, Health Organizations to Study Safety of Medications Taken During Pregnancy 2FDA, Health Organizations to Study Safety of Medications Taken During Pregnancy 3Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010 2
(Date:7/23/2014)... if a suspicious skin lesion is painful or itchy ... to be cancerous, according to a new study headed ... Dermatology at Temple University School of Medicine. , The ... July 23, 2014, found that nearly 36. 9 percent ... 28.2 percent involve pain. Non-melanoma skin cancers specifically, ...
(Date:7/23/2014)... Celebrating a decade of philanthropy in 2014, The ... of $1,070,000 in grants to 20 New Jersey non-profit ... Foundation’s 1,000th grant. , “The Horizon Foundation for New ... community-based organizations that are working to improve public health ... State,” said Robert A. Marino, Horizon Blue Cross Blue ...
(Date:7/23/2014)... Inventor and entrepreneur Delegate Joe T. May will ... pump – sharing his passion for technology and innovation ... , With 24 patents granted and three pending, this ... the General Assembly since Thomas Jefferson. Inventions credited to ... seen on television, an instrument for measuring octane on ...
(Date:7/23/2014)... News) -- Regularly checking the pulse of a stroke ... "Screening pulse is the method of choice for checking ... have never had a stroke. Our study shows it ... to identify people who might need more thorough monitoring ... Bernd Kallmunzer, of Erlangen University in Germany. ...
(Date:7/23/2014)... in Shaanxi province, and the University of California, Davis, ... groundwork for establishing the Sino-U.S. Joint Research Center for ... held in the city of Yingchuan, China, during a ... Agriculture and China,s Ministry of Science and Technology. , ... and for our World Food Center and serves as ...
Breaking Medicine News(10 mins):Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5Health News:Celebrating Innovation and Invention 2Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3
... older women need screening as much as younger ones, ... screening should continue for women older than 50 -- ... because they have a similar level of risk as ... suggested there,s little benefit in repeating smear tests in ...
... recovered from unique virus , , THURSDAY, April 23 (HealthDay ... now been diagnosed with a unique form of swine ... people have recovered, Dr. Anne Schuchat, director of the ... for Immunization and Respiratory Diseases, said during an afternoon ...
... EFFINGHAM, Ill., April 23 Heartland Dental Care, Inc. ... care facilities during first quarter 2009.The six acquisitions include ... Phoenix, Ariz., Glendale, Ariz., and New Port Richie, Fla. ... locations in Lee,s Summit, Mo. and Dulles, Va. This ...
... WASHINGTON, April 23 The Food and Drug Administration ... expanded over-the-counter access to the morning-after pill, Levonorgestrel or ... adults. Deirdre McQuade, Assistant Director for Policy and Communications ... Pro-Life Activities, objected to the move in the following ...
... can be significantly reduced by providing a simple intervention ... and alternatives of various imaging modalities, according to a ... Island, NY. , "Given the increased awareness ... medical imaging we hypothesized that a simple intervention of ...
... Minn. -- An important genetic study conducted through ... alcoholism in subjects with European ancestry, according to ... Experimental Research . , Research findings ... specific genes and their variations associated with this ...
Cached Medicine News:Health News:Don't Lower Age for Cervical Cancer Test, Study Urges 2Health News:Swine Flu Cases Now Total 7: CDC 2Health News:Heartland Dental Care, Inc. Adds Eight Dental Practices In First Quarter 2009 2Health News:Pro-Life Spokeswoman Objects to FDA Approval of 'Morning-After Pill' for Minors Without Prescription 2Health News:Mayo clinic study finds gene bringing together animal and human research in alcoholism 2
... is pouncing on the T.L.I.F. market as the ... of CFRP clinical history and the amazing success ... Leopard is sure to be king of the ... from 7-18 mm in height. The footprint is ...
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
Anterior Interbody fusion with proven clinical performance. Large hole design. Request info fda status for sale....
... transmitted through sorted fiberglass bundles ... transmit it to a user's ... designed for rough, industrial handling ... low cost if they should ...
Medicine Products: